Anne Gedebjerg

Anne Gedebjerg

Auto-generated profile, based on publicly available information

Anne Gedebjerg

Department of Clinical Epidemiology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
AGAnne Gedebjerg
Anne Gedebjerg
TAThomas Peter Almdal
Thomas Peter Almdal
KBKlara Berencsi
Klara Berencsi
JRJørgen Rungby
Jørgen Rungby
JNJens Steen Nielsen
Jens Steen Nielsen
RTReimar Wernich Thomsen
Reimar Wernich Thomsen

1 March 2018 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
AGAnne Gedebjerg
Anne Gedebjerg
SSSzimonetta Komjáthiné Szépligeti
Szimonetta Komjáthiné Szépligeti
LWLaura-Maria Holm Wackerhausen
Laura-Maria Holm Wackerhausen
EHErzsébet Horváth-Puhó
Erzsébet Horváth-Puhó
RDRonald Dahl
Ronald Dahl
RTReimar Wernich Thomsen
Reimar Wernich Thomsen

17 March 2023 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
AGAnne Gedebjerg
Anne Gedebjerg
MBMette Bjerre
Mette Bjerre
AKAlisa Devedzic Kjaergaard
Alisa Devedzic Kjaergaard
JNJens Steen Nielsen
Jens Steen Nielsen
JRJørgen Rungby
Jørgen Rungby
RTReimar Wernich Thomsen
Reimar Wernich Thomsen
OBJECTIVE: We investigated the relationship between hs-CRP, a marker of low-grade inflammation, alone or in combination with C-peptide, a marker of hyperinsulinemia/insulin resistance, and risk for cardiovascular events (CVEs) and mortality in patients recently diagnosed with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: In patients with recent-onset T2D, we measured serum hs-CRP (n = 7,301) and C-peptide (n = 5,765) in the prospective Danish Centre for Strategic Research in Type 2 Diabetes cohort study. Patients with no prior CVE (n = 6,407) were followed until first myocardial infarction, stroke, coronary revascularization, or cardiovascular death, and all patients (n = 7,301) were followed for all-cause mortality. We computed adjusted hazard ratios (aHRs) by Cox regression and tested for the interaction between hs-CRP and C-peptide. RESULTS: During follow-up (median 4.8 years), high (>3 mg/L) versus low (<1 mg/L) hs-CRP was associated with increased CVE risk (aHR 1.45 [95% CI 1.07–1.96]) and with even greater risk of all-cause mortality (2.47 [1.88–3.25]). Compared with patients with low hs-CRP (≤3 mg/L) and low C-peptide (<1,470 pmol/L), those with high levels of both biomarkers had the highest CVE (1.61 [1.10–2.34]) and all-cause mortality risk (2.36 [1.73–3.21]). Among patients with high C-peptide, risk of CVEs did not differ by low or high hs-CRP, whereas risk of all-cause mortality did. CONCLUSIONS: The finding of high hs-CRP as a stronger prognostic biomarker of all-cause mortality than of CVEs may facilitate improved early detection and prevention of deadly diseases besides CVEs. Conversely, elevated C-peptide as a strong CVE biomarker supports the need to target hyperinsulinemia/insulin resistance in T2D CVE prevention.

1 January 2019 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
LDLaura Boysen Dall
Laura Boysen Dall
KLKaren Rokkedal Lausch
Karen Rokkedal Lausch
AGAnne Gedebjerg
Anne Gedebjerg
KFKurt Fuursted
Kurt Fuursted
MSMerete Storgaard
Merete Storgaard
CLCarsten Schade Larsen
Carsten Schade Larsen

2 July 2020 in Diabetes Care
Verified
Journal Article
Open access
PDF file
AGAnne Gedebjerg
Anne Gedebjerg
MBMette Bjerre
Mette Bjerre
AKAlisa Kjaergaard
Alisa Kjaergaard
RSRudi Steffensen
Rudi Steffensen
JNJens Steen Nielsen
Jens Steen Nielsen
RTReimar Wernich Thomsen
Reimar Wernich Thomsen
OBJECTIVE: Mannose-binding lectin (MBL) is linked to risk of cardiovascular disease (CVD) in diabetes, but the nature of the association is unclear. We investigated the association between MBL and the risk of cardiovascular events (CVE) and all-cause mortality in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 7,588 patients with type 2 diabetes, we measured serum MBL in 7,305 patients and performed MBL expression genotyping in 3,043 patients. We grouped serum MBL and MBL expression genotypes into three categories: low, intermediate, and high. Outcomes were CVE (myocardial infarction, stroke, coronary revascularization, unstable angina, or cardiovascular death) and all-cause mortality. The association with outcomes was examined by spline and Cox regression analyses. RESULTS: Serum MBL and CVE showed a U-shaped association. Compared with the intermediate serum MBL category, the adjusted hazard ratio (HR) for CVE was 1.82 (95% CI 1.34–2.46) for the low-MBL category and 1.48 (95% CI 1.14–1.92) for the high-MBL category. We found a similar U-shaped association for all-cause mortality, but with lower risk estimates. Compared with the intermediate MBL expression genotype, the adjusted HR for CVE was 1.40 (95% CI 0.87–2.25) for the low-expression genotype and 1.44 (95% CI 1.01–2.06) for the high-expression genotype. MBL expression genotype was not associated with all-cause mortality. CONCLUSIONS: Both serum MBL and MBL expression genotype showed a U-shaped association with CVE risk in individuals with type 2 diabetes. Our findings suggest that serum MBL is a risk factor for CVD in this population.

1 May 2021 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
AGAnne Gedebjerg
Anne Gedebjerg
RTReimar Wernich Thomsen
Reimar Wernich Thomsen
AKAlisa Devedzic Kjaergaard
Alisa Devedzic Kjaergaard
RSRudi Steffensen
Rudi Steffensen
JNJens Steen Nielsen
Jens Steen Nielsen
MBMette Bjerre
Mette Bjerre